Sequoia Vaccines, a Phase 1 biotech developing a vaccine for recurrent UTIs and small molecules for cancers, filed on Monday with the SEC to raise up to $20 million in an initial public offering.
Sequoia Vaccines is focused on developing a vaccine to prevent recurrent urinary tract infections (UTIs), as well as small molecules for cancers and bacterial infections. The company's lead candidate, SEQ-400, is designed to generate antibodies that function to reduce the bacterial attachment and colonization of human bladders to prevent UTIs. Sequoia successfully completed a Phase 1 study of SEQ-400 in healthy volunteers and women with a history of recurrent UTIs, and it plans to commence a Phase 2 efficacy trial in 2024.
The St. Louis, MO-based company was founded in 2012 and plans to list on the NYSE American under the symbol SQVI. Sequoia Vaccines filed confidentially on August 24, 2023. ThinkEquity is the sole bookrunner on the deal. No pricing terms were disclosed.
